Aquestive Therapeutics Inc
AQST5.990USD
+0.020+0.34%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
728.73MMarket Cap
LossP/E TTM
More Details of Aquestive Therapeutics Inc Company
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Aquestive Therapeutics Inc Info
Ticker SymbolAQST
Company nameAquestive Therapeutics Inc
IPO dateJul 25, 2018
CEOBarber (Daniel R)
Number of employees142
Security typeOrdinary Share
Fiscal year-endJul 25
Address30 Technology Dr
CityWARREN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07059-5166
Phone19089411900
Websitehttps://aquestive.com/
Ticker SymbolAQST
IPO dateJul 25, 2018
CEOBarber (Daniel R)
Company Executives of Aquestive Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.76M
-4.97%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
288.11K
+7.46%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-6.70%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
239.09K
-15.12%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
181.86K
+15.94%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
75.08K
--
Dr. Marco Taglietti, M.D.
Dr. Marco Taglietti, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy E. Morris, CPA
Mr. Timothy E. Morris, CPA
Independent Director
Independent Director
--
--
Ms. Stephanie Carrington
Ms. Stephanie Carrington
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel Barber
Mr. Daniel Barber
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.76M
-4.97%
Ms. Lori J. Braender, J.D.
Ms. Lori J. Braender, J.D.
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
Chief Legal Officer, Chief Compliance Officer and Corporate Secretary
649.24K
+36.11%
Mr. Peter E. Boyd
Mr. Peter E. Boyd
Senior Vice President - Information Technology, Human Resources and Communications
Senior Vice President - Information Technology, Human Resources and Communications
288.11K
+7.46%
Dr. Carl N. Kraus, M.D.
Dr. Carl N. Kraus, M.D.
Chief Medical Officer
Chief Medical Officer
282.48K
-6.70%
Ms. Cassie Jung
Ms. Cassie Jung
Chief Operating Officer
Chief Operating Officer
239.09K
-15.12%
Ms. Sherry Korczynski
Ms. Sherry Korczynski
Chief Commercial Officer
Chief Commercial Officer
181.86K
+15.94%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Ex-United States
5.11M
0.00%
United States
4.89M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Crestline Investors, Inc.
8.04%
RTW Investments L.P.
5.12%
BlackRock Institutional Trust Company, N.A.
4.82%
The Vanguard Group, Inc.
4.64%
Perceptive Advisors LLC
3.08%
Other
74.29%
Shareholders
Shareholders
Proportion
Crestline Investors, Inc.
8.04%
RTW Investments L.P.
5.12%
BlackRock Institutional Trust Company, N.A.
4.82%
The Vanguard Group, Inc.
4.64%
Perceptive Advisors LLC
3.08%
Other
74.29%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.59%
Hedge Fund
15.35%
Investment Advisor/Hedge Fund
14.96%
Individual Investor
4.78%
Research Firm
3.60%
Private Equity
3.16%
Venture Capital
2.10%
Pension Fund
0.13%
Bank and Trust
0.11%
Other
38.23%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
290
68.88M
51.65%
+53.83K
2025Q3
292
69.42M
52.46%
+17.93M
2025Q2
259
51.52M
60.81%
+3.12M
2025Q1
254
48.51M
53.81%
-4.93M
2024Q4
235
47.80M
61.37%
-3.43M
2024Q3
221
51.10M
56.03%
+7.58M
2024Q2
183
43.39M
51.75%
+1.05M
2024Q1
153
42.09M
27.96%
+16.79M
2023Q4
116
23.79M
35.83%
+799.63K
2023Q3
117
22.90M
31.32%
+3.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Crestline Investors, Inc.
9.81M
8.13%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.89M
4.88%
+448.94K
+8.25%
Jun 30, 2025
The Vanguard Group, Inc.
4.33M
3.59%
+254.95K
+6.26%
Jun 30, 2025
Perceptive Advisors LLC
2.19M
1.82%
-1.54M
-41.23%
Jun 30, 2025
Armistice Capital LLC
2.75M
2.28%
+2.75M
--
Sep 30, 2024
Geode Capital Management, L.L.C.
1.98M
1.64%
+276.30K
+16.25%
Jun 30, 2025
Barber (Daniel R)
1.76M
1.46%
-91.74K
-4.97%
Sep 26, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.97%
Federated Hermes MDT Small Cap Core ETF
0.41%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Vanguard US Momentum Factor ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.97%
Federated Hermes MDT Small Cap Core ETF
Proportion0.41%
iShares Micro-Cap ETF
Proportion0.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.09%
Invesco Nasdaq Biotechnology ETF
Proportion0.08%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.04%
Vanguard US Momentum Factor ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Aquestive Therapeutics Inc?
The top five shareholders of Aquestive Therapeutics Inc are:
Crestline Investors, Inc. holds 9.81M shares, accounting for 8.13% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.89M shares, accounting for 4.88% of the total shares.
The Vanguard Group, Inc. holds 4.33M shares, accounting for 3.59% of the total shares.
Perceptive Advisors LLC holds 2.19M shares, accounting for 1.82% of the total shares.
Armistice Capital LLC holds 2.75M shares, accounting for 2.28% of the total shares.
Crestline Investors, Inc. holds 9.81M shares, accounting for 8.13% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 5.89M shares, accounting for 4.88% of the total shares.
The Vanguard Group, Inc. holds 4.33M shares, accounting for 3.59% of the total shares.
Perceptive Advisors LLC holds 2.19M shares, accounting for 1.82% of the total shares.
Armistice Capital LLC holds 2.75M shares, accounting for 2.28% of the total shares.
What are the top three shareholder types of Aquestive Therapeutics Inc?
The top three shareholder types of Aquestive Therapeutics Inc are:
Crestline Investors, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
Crestline Investors, Inc.
RTW Investments L.P.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Aquestive Therapeutics Inc (AQST)?
As of 2025Q4, 290 institutions hold shares of Aquestive Therapeutics Inc, with a combined market value of approximately 68.88M, accounting for 51.65% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.81%.
What is the biggest source of revenue for Aquestive Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Aquestive Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
